Union Bancaire Privee UBP SA Sells 1,770 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Union Bancaire Privee UBP SA lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 47.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,951 shares of the company's stock after selling 1,770 shares during the quarter. Union Bancaire Privee UBP SA's holdings in IDEXX Laboratories were worth $824,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Norges Bank bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at $412,258,000. GAMMA Investing LLC increased its position in IDEXX Laboratories by 59,810.7% during the first quarter. GAMMA Investing LLC now owns 918,431 shares of the company's stock worth $3,856,950,000 after buying an additional 916,898 shares during the last quarter. Flossbach Von Storch SE increased its position in IDEXX Laboratories by 5,439.3% during the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock worth $195,696,000 after buying an additional 464,791 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in IDEXX Laboratories during the fourth quarter valued at about $156,412,000. Finally, William Blair Investment Management LLC lifted its position in shares of IDEXX Laboratories by 701.6% in the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company's stock worth $174,527,000 after buying an additional 369,471 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX traded down $4.22 during mid-day trading on Friday, hitting $522.70. 411,464 shares of the company's stock traded hands, compared to its average volume of 649,556. The firm has a market capitalization of $42.04 billion, a price-to-earnings ratio of 48.99, a price-to-earnings-growth ratio of 3.41 and a beta of 1.55. The firm has a 50 day moving average of $469.88 and a two-hundred day moving average of $443.57. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $537.00.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company's quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.71 earnings per share. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Stifel Nicolaus increased their price objective on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Leerink Partners upped their target price on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research report on Wednesday. Morgan Stanley increased their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Four equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $546.00.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of the business's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the transaction, the director now directly owns 1,801 shares in the company, valued at $922,724.34. The trade was a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.98% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.